Year-end report January-December 2009

  * The Group's sales for the period amounted to SEK 634 (580) million
  * EBITDA amounted to SEK 98 (72) million
  * EBIT amounted to SEK 71(1)()) (57) million
  * The net profit after tax for the period amounted to SEK 18(1)) (32)
    million(2))
  * Earnings per share after tax for the period were SEK 0.05 (0.13 )(2) )before
    and after dilution



Significant events during the period

  * The capital acquisition implemented in Q2 was fully subscribed, bringing
    BioPhausia proceeds of SEK 64 million before expenses.
  * Generic product sales were launched in Poland towards the end of Q3.
  * Novalucol was named as one of the limited number of non-prescription drugs
    cleared for sale in the large supermarket chains.
  * In the 3rd quarter, 58% of the available warrants under the incentive
    programme were acquired by personnel.



Period October-December

  * The Group's sales for the quarter amounted to SEK 153 (168) million
  * EBITDA amounted to SEK 23 (23) million
  * Operating profit was SEK 13(1) )(18) million
  * Profit after tax amounted to SEK 2(1)) (-2) million
  * Earnings per share after tax was SEK 0.01 (neg) before and after dilution



Significant events after the period

  * Claes Thulin is to leave BioPhausia. Recruitment of a new CEO is underway.
  * The Board has decided to initiate a process to review the communicated
    financial targets.





Stockholm 12 of February 2010


CLAES THULIN

CHIEF EXECUTIVE OFFICER


FOR FURTHER INFORMATION

Claes Thulin CEO, +46-8-407 64 30

www.biophausia.se <http://www.biophausia.se>



[HUG#1385233]
Year-end report January-December 2009

Attachments
